These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37918013)

  • 41. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
    Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
    JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients.
    Szkandera J; Pichler M; Absenger G; Stotz M; Arminger F; Weissmueller M; Schaberl-Moser R; Samonigg H; Kornprat P; Stojakovic T; Avian A; Gerger A
    Am J Surg; 2014 Aug; 208(2):210-4. PubMed ID: 24581872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer.
    Wang L; Hirano Y; Ishii T; Kondo H; Hara K; Obara N; Yamaguchi S
    World J Surg Oncol; 2020 Mar; 18(1):54. PubMed ID: 32160919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative prognostic nutritional index predicts risk of recurrence after curative resection for stage IIA colon cancer.
    Maruyama T; Shimoda M; Hakoda H; Sako A; Ueda K; Suzuki S
    Am J Surg; 2021 Jul; 222(1):179-185. PubMed ID: 33138968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prognostic value of a predictive model comprising preoperative inflammatory response and nutritional indexes in patients with gastric cancer].
    Wu LL; Cai MZ; Wang BG; Deng JY; Ke B; Zhang RP; Liang H; Wang XN
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):680-688. PubMed ID: 37583026
    [No Abstract]   [Full Text] [Related]  

  • 46. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
    J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.
    Sinicrope FA; Foster NR; Yothers G; Benson A; Seitz JF; Labianca R; Goldberg RM; Degramont A; O'Connell MJ; Sargent DJ;
    Cancer; 2013 Apr; 119(8):1528-36. PubMed ID: 23310947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma.
    Li J; Jiang R; Liu WS; Liu Q; Xu M; Feng QS; Chen LZ; Bei JX; Chen MY; Zeng YX
    PLoS One; 2013; 8(12):e83069. PubMed ID: 24386144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
    Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
    Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
    Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
    JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
    Donada M; Bonin S; Barbazza R; Pettirosso D; Stanta G
    BMC Gastroenterol; 2013 Feb; 13():36. PubMed ID: 23446022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic impact of tumour sidedness in patients with stage II colon cancer: a single-centre retrospective study.
    Iguchi K; Mushiake H; Fukushima T; Rino Y; Masuda M
    ANZ J Surg; 2021 Apr; 91(4):E196-E202. PubMed ID: 33559326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.
    Auclin E; André T; Taieb J; Banzi M; Van Laethem JL; Tabernero J; Hickish T; de Gramont A; Vernerey D
    Br J Cancer; 2019 Aug; 121(4):312-317. PubMed ID: 31296923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
    Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
    Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of the Collagen Signature in the Tumor Microenvironment With Recurrence and Survival of Patients With T4N0M0 Colon Cancer.
    Chen W; Dong S; Liu X; Wang G; Xu S; Lei S; Zhuo S; Yan J
    Dis Colon Rectum; 2021 May; 64(5):563-575. PubMed ID: 33538520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
    Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
    Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.